Evidence map›Paper›PMID 21475772›Full record

ArticleThrombosis and haemostasis2011

A novel family of RGD-containing disintegrins (Tablysin-15) from the salivary gland of the horsefly Tabanus yao targets αIIbβ3 or αVβ3 and inhibits platelet aggregation and angiogenesis.

D Ma, X Xu, S An, H Liu, X Yang, J F Andersen, Y Wang, F Tokumasu, J M C Ribeiro, I M B Francischetti and 1 more

Open access · greenAbstract read
In one paragraph

Article in Thrombosis and haemostasis, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 62 citations in OpenAlex.

  1. Review
  2. Article
  3. Tick-Derived Peptide Blocks Potassium Channel TREK-1.International journal of molecular sciences · 2024
    Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. FM-CATH, A Novel Cathelicidin FromFrontiers in pharmacology · 2021
    Article
  11. Article
  12. Frontiers in chemistry · 2020
    Article
  13. Article
  14. Article
  15. Article
  16. A Short Half-Life αInternational journal of molecular sciences · 2018
    Article
  17. Article
  18. Article
  19. Beyond the Matrix: The Many Non-ECM Ligands for Integrins.International journal of molecular sciences · 2018
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

D MaKunming Institute of Zoology, Chinese Academy of Sciences, Kunming 650223, Yunnan, China.
X Xu
S An
H Liu
X Yang
J F Andersen
Y Wang
F Tokumasu
J M C Ribeiro
I M B Francischetti
R Lai
National Institutes of Health · USKunming Institute of Zoology · CN

Funding

Vector-Borne Diseases: Biology Of Vector Host RelationshipZIAAI000810 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RIBEIRO, JOSE · 2009 to 2025
$20.8M
Vector-Borne Diseases: Molecular Mechanisms in Vector-Host InteractionsZIAAI001012 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RIBEIRO, JOSE · 2009 to 2025
$9.4M
Vector-Borne Diseases: Biology Of Vector Host RelationshipZ01AI000810 · NIAID · NIAID EXTRAMURAL ACTIVITIES · PI RIBEIRO, JOSE M · 1997 to 2008
$3.5M
Biochemical And Biophysical ParasitologyZIAAI000099 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI WELLEMS, THOMAS E · 2009 to 2014
$1.8M
Intramural NIH HHS Z01 AI000810Intramural NIH HHS Z99 AI999999NIAID NIH HHS Y99 AI999999
6 · The paper itself

Abstract

A novel family of RGD-containing molecules (Tablysin-15) has been molecularly characterised from the salivary gland of the haematophagous horsefly Tabanus yao. Tablysin-15 does not share primary sequence homology to any disintegrin discovered so far, and displays an RGD motif in the N-terminus of the molecule. It is also distinct from disintegrins from Viperidae since its mature form is not released from a metalloproteinase precursor. Tablysin-15 exhibits high affinity binding for platelet αIIbβ3 and endothelial cell αVβ3 integrins, but not for α5β1 or α2β1. Accordingly, it blocks endothelial cell adhesion to vitronectin (IC50 ~1 nM) and marginally to fibronectin (IC50 ~1 μM), but not to collagen. It also inhibits fibroblast growth factor (FGF)-induced endothelial cell proliferation, and attenuates tube formation in vitro. In platelets, Tablysin-15 inhibits aggregation induced by collagen, ADP and convulxin, and prevents static platelet adhesion to immobilised fibrinogen. In addition, solid-phase assays and flow cytometry demonstrates that αIIbβ3 binds to Tablysin-15. Moreover, immobilised Tablysin-15 supports platelet adhesion by a mechanism which was blocked by anti-integrin αIIbβ3 monoclonal antibody (e.g. abciximab) or by EDTA. Furthermore, Tablysin-15 dose-dependently attenuates thrombus formation to collagen under flow. Consistent with these findings, Tablysin-15 displays antithrombotic properties in vivo suggesting that it is a useful tool to block αIIbβ3, or as a prototype to develop antithrombotics. The RGD motif in the unique sequence of Tablysin-15 represents a novel template for studying the structure-function relationship of the disintegrin family of inhibitors.

Indexed as

Angiogenesis InhibitorsAnimalsAntibodies, MonoclonalBlood PlateletsCell AdhesionCell ProliferationDipteraDisintegrinsEndothelial CellsInsect ProteinsIntegrin alpha2Integrin alpha5Integrin beta3OligopeptidesPlatelet Aggregation InhibitorsProtein BindingAngiogenesis InhibitorsAntibodies, Monoclonalarginyl-glycyl-aspartic acidDisintegrinsInsect ProteinsIntegrin alpha2Integrin alpha5Integrin beta3OligopeptidesPlatelet Aggregation InhibitorsSalivary Proteins and Peptidestablysin-15, Tabanus yao

Identifiers

PMID21475772
PMCPMC3499621
OpenAlexW1970312745

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.